Prot. Number IA-001: A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating the Safety, Pharmacokinetics and Clinical Benefit of FLU-IGIV in Hospitalized Patients with Serious Influenza A Infection

Project: Research project

StatusActive
Effective start/end date12/15/1712/15/20

Funding

  • SGS North America Inc. (Protocol no. IA-001)
  • Cangene Corporation (Protocol no. IA-001)